Is Inovio Gaining Ground in the Coronavirus Vaccine Race?
Moderna (NASDAQ: MRNA) was the first maker of a vaccine for the novel coronavirus to enter clinical trials, but fellow clinical-stage biotech Inovio Pharmaceuticals (NASDAQ: INO) is close behind. Inovio, during its earnings call this week, said it recently completed enrollment in a phase 1 trial.
Victory in this race, though, doesn't depend only on which company enters human trials first. It depends on several factors, including the results of the trials, the ability to manufacture enough doses, and the funding for each project.
There are currently more than 70 vaccine candidates in development for COVID-19, the illness caused by the novel coronavirus, according to the World Health Organization. Moderna and Inovio are among the five vaccine makers that have begun human trials.
Source Fool.com
